Clinical trials conducted recently on therapies that aim at the programmed cell death protein‐1 (PD‐1) and programmed death‐ligand 1 (PD‐L1) pathway, known as PD‐(L)1 inhibitors, have exhibited clinical benefit compared to docetaxel for patients who have advanced refractory NSCLC.12, 13, 14, 15, 16, 17. The gene discussed is CD274; the disease is non-small cell lung carcinoma.